Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUROPE trial: Predictive model of response to romiplostim in low/int-1 risk MDS with thrombocytopenia
2013-004328-12Phase 2Completed
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of romiplostim in myelodysplastic syndrome (MDS) and Thrombocytopenia, sponsored by GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH. Primary endpoint: Hematologic improvement of platelets after 4 months. Started Oct 2014; status: completed.
02
Drugs
romiplostim
03
Conditions
myelodysplastic syndrome (MDS)Thrombocytopenia
Beyond the preview
Go deeper on 2013-004328-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004328-12.